Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Global Oil Traders Fuel Kineta’s Drug Pipeline

Published: Wednesday, May 22, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
Kineta, Inc. and Hydra, LLC announced the completion of a major investment to add funding to Kineta’s clinical-stage drug programs.

The investment is directed at Kineta’s two lead drug programs - ShK-186, a novel immune-sparing targeted therapeutic focused on autoimmune diseases, and rOAS, a novel pan-viral therapeutic aimed at an array of high-priority contagious pathogens for which there are few effective therapies.

“We are genuinely impressed with Kineta’s leadership and laser-focus on delivering high-caliber R&D to larger global pharmaceutical companies. This is a nimble organization with a track record of development success. Kineta has created a unique, cost-efficient and rational way to move early-stage drug programs into human subjects with a focus on rapidly delivering liquidity. All of these factors went into our investment decision,” explained Jamie Browne, a managing director of Hydra, LLC.

Mr. Browne co-leads Hydra, LLC, along with Ken Backes. Hydra is comprised of 13 recently retired Glencore Ltd. traders. Each Hydra member has committed considerable capital to the new private equity partnership. Hydra is focused on diversified opportunities, including choosing to provide Kineta, Inc., significant funding to make major clinical advancements in two drug development programs.

“Kineta is very pleased to welcome Hydra as a major investor into our clinical-stage programs. This is a team of highly astute investors with broad appreciation for underlying market forces across economic sectors. Their investment is a tremendous vote of confidence for the Kineta model and will enable us to advance our clinical work for two very promising drug candidates,” said Kineta, Inc., President and CEO Charles Magness, Ph.D.

Kineta’s lead program, Shk-186, recently completed phase one studies, successfully positioning it for multiple development pathways for autoimmune diseases. Kineta’s second program, rOAS, is scheduled to enter first-in-human clinical trials later this year. Kineta’s pipeline also contains three additional drug and vaccine adjuvant programs; all have novel mechanisms of action and are aimed at large, global unmet medical needs. Kineta has raised more than $46M since 2008 through grants and private investment. Kineta’s chief business goal is to partner or license clinically validated assets that have achieved pre-specified development milestones to pharmaceutical companies for further clinical development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!